TLR4 and chorioamnionitis: Our preclinical studies suggest that the attenuation of eNAMPT/TLR4 inflammatory signaling is a potentially novel therapeutic strategy to reduce maternal and fetal/neonatal morbidities and mortalities as well as prematurity in human pregnancies complicated by IAI/chorioamnionitis.